Top 10 Companies in the (S)-4-Fluorophenyl glycine (CAS 19883-57-9) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (S)-4-Fluorophenyl glycine (CAS 19883-57-9) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.6 million by 2034, exhibiting a CAGR of 7.2% during the forecast period.

(S)-4-Fluorophenyl glycine is a non-proteinogenic, enantiomerically pure amino acid derivative featuring a fluorine-substituted phenyl ring, recognized for its distinct stereochemical properties and high chemical stability. It serves as a critical chiral building block in the synthesis of active pharmaceutical ingredients (APIs), peptide-based therapeutics, and specialty agrochemicals. Its fluorine substitution enhances metabolic stability and membrane permeability, making it particularly valuable in drug discovery and medicinal chemistry applications.

The market is witnessing steady growth driven by rising demand for chiral intermediates in pharmaceutical synthesis, growing investments in asymmetric synthesis research, and expanding applications in the development of fluorine-containing drug candidates. Furthermore, the increasing focus on enantioselective manufacturing processes across the fine chemicals sector continues to strengthen demand for high-purity (S)-configured amino acid derivatives such as this compound.

(S)-4-Fluorophenyl glycine (CAS 19883-57-9) Market – View in Detailed Research Report

Top 10 Companies in the (S)-4-Fluorophenyl glycine Market

1. Fluorochem Ltd.

Headquarters: United Kingdom
Key Offering: High-purity (S)-4-Fluorophenyl glycine for API synthesis and peptide development

Fluorochem Ltd. is a leading specialty chemical supplier with a robust GMP-compliant manufacturing base. The company offers a range of enantiopure intermediates, including (S)-4-Fluorophenyl glycine, tailored for pharmaceutical R&D and CDMO projects.

Sustainability & Growth Initiatives:

• Investment in continuous flow synthesis to reduce waste
• Partnerships with major pharma for early-stage discovery
• Development of eco-friendly purification protocols

2. ABCR GmbH

Headquarters: Germany
Key Offering: Ultra-high purity (S)-4-Fluorophenyl glycine for regulated APIs

ABCR GmbH specializes in chiral fine chemicals with stringent impurity profiles. Their (S)-4-Fluorophenyl glycine is certified for use in GMP manufacturing of small-molecule drugs.

Sustainability & Growth Initiatives:

• Adoption of renewable energy in production facilities
• Development of greener catalytic systems for asymmetric synthesis
• Active engagement in regulatory science forums

3. Combi-Blocks Inc.

Headquarters: United States
Key Offering: Custom synthesis of (S)-4-Fluorophenyl glycine for academic and biotech research

Combi-Blocks Inc. provides on-demand, small-batch production of chiral building blocks. Their flexible platform enables rapid delivery of (S)-4-Fluorophenyl glycine to early-stage discovery labs.

Sustainability & Growth Initiatives:

• Use of biocatalysts for scalable synthesis
• Implementation of closed-loop water systems
• Collaboration with universities for process innovation

4. Oakwood Chemical

Headquarters: United States
Key Offering: High-purity (S)-4-Fluorophenyl glycine for peptide therapeutics and agrochemical R&D

Oakwood Chemical delivers both technical and pharmaceutical grade (S)-4-Fluorophenyl glycine, supporting research into peptidomimetics and fluorinated agrochemicals.

Sustainability & Growth Initiatives:

• Zero-waste manufacturing targets
• Investment in solvent-recycling technologies
• Partnerships with green chemistry consortia

5. Hanhong Group (Hanhong Chemical)

Headquarters: China
Key Offering: Cost-competitive (S)-4-Fluorophenyl glycine for large-scale API production

Hanhong Group leverages advanced asymmetric hydrogenation processes to supply high-volume, high-purity (S)-4-Fluorophenyl glycine to the Asia-Pacific pharmaceutical market.

Sustainability & Growth Initiatives:

• Energy-efficient reactor design
• Scale-up of enzymatic resolution for greener synthesis
• Participation in regional supply-chain resilience programs

6. Zhejiang Jiaxing Fulong Chemical

Headquarters: China
Key Offering: Custom and bulk (S)-4-Fluorophenyl glycine for pharma and biotech

Jiaxing Fulong Chemical offers tailored synthesis routes, including biocatalytic and flow chemistry, to meet diverse customer needs.

Sustainability & Growth Initiatives:

• Implementation of green solvent systems
• Investment in process analytical technology (PAT)
• Collaboration with local universities for talent development

7. Jinan Chenghui-Shuangda Chemical

Headquarters: China
Key Offering: Small-to-medium batch (S)-4-Fluorophenyl glycine for research institutions

Jinan Chenghui-Shuangda specializes in rapid custom synthesis, enabling quick turnaround for academic and early-stage biotech projects.

Sustainability & Growth Initiatives:

• Use of renewable feedstocks
• Development of modular synthesis units
• Active participation in industry standards groups

8. Nanjing Chemlin Chemical Industry

Headquarters: China
Key Offering: High-purity (S)-4-Fluorophenyl glycine for regulated API production

Nanjing Chemlin provides GMP-grade intermediates with comprehensive analytical data, supporting drug master file (DMF) submissions.

Sustainability & Growth Initiatives:

• Energy-saving manufacturing upgrades
• Implementation of real-time monitoring systems
• Engagement in cross-industry research consortia

9. Tokyo Chemical Industry Co., Ltd. (TCI)

Headquarters: Japan
Key Offering: Premium (S)-4-Fluorophenyl glycine for pharmaceutical and agrochemical sectors

TCI offers a portfolio of chiral intermediates with strict purity specifications, catering to both domestic and international markets.

Sustainability & Growth Initiatives:

• Adoption of carbon-neutral production processes
• Investment in biocatalytic technology
• Collaboration with global pharma for early-stage development

10. Lonza Group

Headquarters: Switzerland
Key Offering: Comprehensive CDMO services including (S)-4-Fluorophenyl glycine synthesis for peptide therapeutics

Lonza combines proprietary synthesis platforms with extensive regulatory experience, delivering (S)-4-Fluorophenyl glycine as part of integrated drug development solutions.

Sustainability & Growth Initiatives:

• Zero-waste manufacturing commitments
• Development of sustainable catalytic systems
• Active role in global sustainability initiatives

Download FREE Sample Report: (S)-4-Fluorophenyl glycine (CAS 19883-57-9) Market – View in Detailed Research Report

Get Full Report Here: (S)-4-Fluorophenyl glycine (CAS 19883-57-9) Market – View in Detailed Research Report

Market Outlook

The (S)-4-Fluorophenyl glycine market is poised for robust expansion, driven by the convergence of fluorine chemistry and chiral synthesis. The increasing prevalence of peptide-based therapeutics, coupled with stringent regulatory requirements for chiral purity, will continue to fuel demand. Manufacturers that invest in scalable asymmetric synthesis and maintain rigorous quality systems will capture the largest share of this niche yet growing market.

Future Trends

• Adoption of continuous flow asymmetric synthesis for higher yield and lower cost.
• Expansion of (S)-4-Fluorophenyl glycine into agrochemical development, leveraging its selectivity.
• Growth of CDMO and CRO services, increasing demand for custom chiral intermediates.
• Integration of AI-driven process optimization to reduce development timelines.
• Greater emphasis on sustainability, including renewable feedstocks and zero-waste production.